Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Assets Average (2021 - 2026)

Cytek Biosciences filings provide 5 years of Assets Average readings, the most recent being $478.2 million for Q4 2025.

  • On a quarterly basis, Assets Average fell 3.46% to $478.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $478.2 million, a 3.46% decrease, with the full-year FY2025 number at $480.5 million, down 3.31% from a year prior.
  • Assets Average hit $478.2 million in Q4 2025 for Cytek Biosciences, down from $494.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $524.8 million in Q2 2023 to a low of $342.3 million in Q3 2021.
  • Median Assets Average over the past 5 years was $492.2 million (2024), compared with a mean of $486.8 million.
  • Biggest five-year swings in Assets Average: skyrocketed 44.92% in 2022 and later fell 7.03% in 2024.
  • Cytek Biosciences' Assets Average stood at $458.8 million in 2021, then grew by 11.02% to $509.4 million in 2022, then dropped by 0.48% to $506.9 million in 2023, then fell by 2.28% to $495.4 million in 2024, then dropped by 3.46% to $478.2 million in 2025.
  • The last three reported values for Assets Average were $478.2 million (Q4 2025), $494.1 million (Q3 2025), and $488.0 million (Q2 2025) per Business Quant data.